针对抗体中介排斥的新疗法:介于interleukin-6的抑制剂
Byung Hwa Park1,2, Ye Na Kim1,2, Ho Sik Shin1,2
1Division of Nephrology, Department of Internal Medicine, Kosin University Gospel Hospital, Kosin University College of Medicine, Busan, Korea.
Clinical transplantation and research
|May 10, 2024
概括
移植后的抗体中介排斥 (AMR) 涉及对新器官的免疫攻击. 介乐-6 (IL-6) 驱动抗体的产生,使IL-6抑制剂成为一种潜在的AMR新疗法.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學專業.
- 免疫学 免疫学 免疫学
- 移植科学 移植科学
背景情况:
- 移植受到抗体介导排斥 (AMR) 的威胁.
- 在新的人类白细胞抗原供体特异性抗体 (HLA-DSAs) 是AMR的主要驱动因素.
- 目前的AMR治疗包括血酶,IVIg和抗CD20抗体,在耐药病例中成功程度有限.
研究的目的:
- 探索INTERLEUKIN-6 (IL-6) 在AMR病变发生中的作用.
- 评估IL-6抑制剂的潜力,作为对患有AMR的脏移植接受者的新疗法策略.
主要方法:
- 审查关于AMR病原和治疗点的现有文献.
- 分析IL-6在B细胞分化和抗体产生中的作用.
- 研究针对IL-6的当前和新兴治疗策略.
主要成果:
- 洲际蛋白-6 (IL-6) 对于B细胞成熟成为产生HLA-DSAs的血细胞至关重要.
- 阻断IL-6可能会减少对AMR负责的致病性抗体的产生.
- IL-6抑制剂正在研究中,并显示出AMR治疗的前景.
结论:
- 向IL-6是一个有希望的治疗途径,用于管理移植患者的抗体中介排斥.
- 进一步的临床研究是必要的,以验证IL-6抑制剂的疗效和安全性,以改善移植结果.
更多相关视频
相关概念视频
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
131
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
131
01:27Tumor Immunotherapy
518
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
518
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
158
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
158